Ultime notizie per Cigna (NYSE:CI) Azioni

Cigna

Cigna Group

Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 17 million US and 2 million international medical members covered as of September 2024.

The Cigna Group

AMUNDI INDIA B ETF

Citizens, Inc. Class A Common Stock ($1.00 Par)

Citizens Inc

CHINA MENGNIU DAIRY CO by China Mengniu Dairy Co., Ltd.

China Mengniu Dairy Co Ltd

CHINA MENGNIU DARY UN/ADR by China Mengniu Dairy Co., Ltd.

CHAMPION IRON LTD by Champion Iron Limited

Champion Iron Ltd

China Score Inc

BanColombia SA

COMML INTL BK S/ADR by Commercial International Bank Ltd.

Commercial International Bank - Egypt CIB

CIB MARINE BANCSHARES by CIB Marine Bancshares, Inc.

CIB Marine Bancshares Inc

COMMUTY INV BANCORP INC by Community Investors Bancorp, Inc.

Community Investors Bancorp Inc

First Trust NASDAQ Cybersecurity ETF

CIBL Inc

Capitol Investment Corp. VII

CION Investment Corporation 7.50% Notes due 2029

CHINA CONSTR BANK H by China Construction Bank Corp.

China Construction Bank Corp

CHINA CONSTR BK UNSP/ADR by China Construction Bank Corp.

SMS ALTERNATIVES INC by SMS Alternatives Inc.

SMS Alternatives Inc

COSCO SHIPPING HLDGS CO by COSCO SHIPPING Holdings Co Ltd.

COSCO SHIPPING Holdings Co Ltd

COSCO SHP HLDG UNSP/ADR by COSCO SHIPPING Holdings Co Ltd.

Capitol Investment Corp. VI

Victory Portfolios II VictoryShares International High Div Volatility Wt

CLAL INSURANCE ENTERPRISE by CLAL INSURANCE ENTERPRISES HOLDINGS LTD.

CI EMERGING MARKET ALPHA USD UNT ETF

Ciena Corp

CIENA ORD

CHieru Co Ltd

CORPORACION INTERAMER B by Corporacion Intramericano Entretenimiento S.A.

Corporacion Interamericana de Entretenimiento SAB de CV

MFS Intermediate High Income Fund Common Stock

Mfs Intermediate High Income Fund

Cipher Mining Inc

Comp En De Mn Cemig ADS American Depositary Shares

Cia Energetica DE Minas Gerais - Cemig

Comp En De Mn Cemig ADS American Depositary Receipts

Colliers International Group Inc. - Subordinate Voting Shares

Colliers International Group Inc

Concorde International Group Ltd

CI GAMES SA by CI GAMES SA

COMPANHIA ENERG ADR REPG ONE PRF

CHINA MERCHANTS BK CO H by China Merchants Bank Co., Ltd.

China Merchants Bank Co Ltd

CHINA MRCHNTS BK UNSP/ADR by China Merchants Bank Co., Ltd.

CB INDUS PRODUCT HLDG BHD by CB Industrial Product Holding BHD

Blackrock Enhanced Cap&Inc Fund, Inc

CITIC SECURITIES CO LTD H by Citic Securities Co., Ltd.

CITIC Securities Co Ltd

CITIC SECURITIES UNSP/ADR by Citic Securities Co., Ltd.

TIANCI INTERNATIONAL INC by Tianci International Inc.

Tianci International Inc

Credit Suisse Asset Management Income Fund, Inc. Common Stock

Credit Suisse Asset Mgmt Income Fund Inc

VictoryShares International Volatility Wtd ETF

CHINA LIFE INS CO H SHS by China Life Insurance Company Limited

China Life Insurance Co Ltd

CAROLINA MILLS INC by Carolina Mills, Inc.

Chimera Investment Corporation Common Stock

Chimera Investment Corp

CIMB GROUP HLDGS BHD ORD by CIMB Group Holdings BHD

CIMB Group Holdings Bhd

CIMC ENRIC HLDGS LTD ORD by CIMC Enric Holdings Ltd.

CIMC Enric Holdings Ltd

Chimera Investment Corporation 9.000% Senior Notes due 2029

Chimera Investment Corporation 9.250% Senior Notes due 2029

Pideka Group Inc

CIMAREX ENERGY 8 1/8 PFD by Cimarex Energy Co.

Chimera Investment Corporation 8.00% Series A Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series B Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 7.75% Series C Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

Chimera Investment Corporation 8.00% Series D Fixed-to-Floating Rate Cumulative Redeemable Preferred Stock

CHINA INDUSTRIAL GRP INC by China Industrial Group, Inc.

China Industrial Group

ISHRS DOW JONES IND AVRG USD ETF

ISHR DJ IND AVG ETF

Cincinnati Financial Corporation - Common Stock

Cincinnati Financial Corp

Cingulate Inc

COINSILIUM GROUP LTD ORD by Coinsilium Group Ltd.

Coinsilium Group Ltd

CHINA TAIPING INS HLD ORD by China Taiping Insurance Holdings Co Ltd.

China Taiping Insurance Holdings Co Ltd

CI&T Inc

CRUCIAL INNOVATIONS CORP by CRUCIAL INNOVATIONS CORP.

CI GLOBAL ALPHA INNOVATION USD ETF

Deutsche Bank analyst George Hill maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Buy and lowers the price target from $398 to $394.

News

Price Target

Analyst Ratings

Deutsche Bank Maintains Buy on Cigna, Lowers Price Target to $394

Looking into the current session, Cigna Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) shares are trading at $315.58, after a 0.29% decrease. Over the past month, the stock decreased by 8.19%, but over the past year, it actually increased by 7.03%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2024/1730734289_0.png" alt="Past Year Chart" />

<h3>A Look at Cigna P/E Relative to Its Competitors</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Cigna has a lower P/E than the aggregate P/E of 41.35 of the Health Care Providers &amp; Services industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1730734289_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Cigna

Stephens &amp; Co. analyst Scott Fidel reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and maintains $410 price target.

Reiteration

Stephens & Co. Reiterates Overweight on Cigna, Maintains $410 Price Target

RBC Capital analyst Ben Hendrix maintains Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Outperform and lowers the price target from $384 to $377.

RBC Capital Maintains Outperform on Cigna, Lowers Price Target to $377

The agreement includes value-based aspects that are focused on improving customer health, lowering costs and achieving high-quality ratings. Infirmary Health is the largest nonprofit, non-governmental healthcare provider in Alabama. Based in Mobile and Baldwin Counties, Infirmary Health serves 11 counties in southern Alabama as well as the Florida panhandle and southern Mississippi with more than 700 doctors and 6,500 other team members, treating more than 1.5 million patients per year.

Large Cap

Health Care

Contracts

General

Cigna Healthcare And Mobile-Based Infirmary Health Have Reached An Agreement That Allows Cigna Healthcare's Medicare Advantage Customers To Have In-network Access To Infirmary Health's Hospitals, Facilities And Doctors

Risk aversion swept across markets on Thursday as investor disappointment over third-quarter tech earnings triggered the steepest drop in major U.S. indices <a href="https://www.benzinga.com/markets">in nearly two months.</a>
Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) plummeted over 5% by midday trading in New York, on track for its worst session in two years. Although the company surpassed earnings estimates, it forecasted slower growth in its Azure cloud business, dampening future revenue expectations.
Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) also declined by over 4% despite a strong quarterly performance, as the social media giant projected &#8220;significant&#8221; capital expenditure growth next year, particularly for AI infrastructure.
The elite &#8220;Magnificent Seven&#8221; tech group shed nearly $500 billion in market capitalization within a single day after reaching a record high of $16.8 trillion. Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) are set to report earnings after the market close.
In economic news, inflation sent mixed signals for September. The Personal Consumption Expenditures (PCE) price index slowed as expected to 2.1% annually, while the Fed's preferred inflation measure, the core PCE price index, remained at 2.7% year over year, slightly <a href="https://www.benzinga.com/economics/macro-economic-events/24/10/41658542/fed-interest-rate-cuts-expected-but-economists-warn-of-bumpy-course-in-this-last-">above the expected 2.6%.</a>
The S&amp;P 500 dropped 1.4%, and the tech-heavy Nasdaq 100 slid 2.2%, both tracking their worst session since Sept. 6. The CBOE Volatility Index (VIX) surged 12%.
Risk aversion also weighed on commodities, with gold prices dropping 1.7%, marking their worst day since July, and silver plunging 3% after a 2% decline on Wednesday. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) slid 2.4%, and crypto-related stocks suffered significant losses. Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) tumbled over 10% on disappointing earnings, eyeing its worst day since May.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,832.30</td>
<td>-0.7%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,213.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,729.43</td>
<td>-1.4%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,943.07</td>
<td>-2.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:20 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 1.5% to $571.51.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.8% to $418.60.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) tumbled 2.2% to $485.78. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.7% to $219.65.</li>
<li>The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, rising 1.4%. The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 2.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to corporate earnings were: 
<ul>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>), up over 5%, </li>
<li>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), up 1.7%,</li>
<li>Starbucks Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NYSE">SBUX</a>), down 0.6%, </li>
<li>eBay Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EBAY#NASDAQ">EBAY</a>), down over 8%, </li>
<li>MicroStrategy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), up 1.9%,</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>), up 24%,</li>
<li>Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), down 1.8%, </li>
<li>Merck &amp; Company Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), down 2.8%,</li>
<li>Linde plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>), down 2.9%, </li>
<li>Comcast Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>), up 2.9%, </li>
<li>Uber Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), down over 11%, </li>
<li>Eaton Corp. plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>), down 5%, </li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>), up 6%, </li>
<li>Bristo-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), up 3.3%, </li>
<li>Southern Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SO#NYSE">SO</a>), up 2.2%, </li>
<li>Altria Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>), up 7.6%, </li>
<li>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>), down 9%, </li>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), up 3%, </li>
<li>Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>), up over 9%. </li>
<li>Cheniere Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>), up over 5%. </li>
</ul>
Large-cap companies slated to report their earnings after the close include Apple Inc, Amazon.com Inc, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>), Atlassian Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) and Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>).
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41658754/microsoft-in-major-growth-mode-not-slowing-down-4-analysts-see-strong-azure-demand-">Microsoft &#8216;In Major Growth Mode,&#8217; Not Slowing Down: 4 Analysts See Strong Azure Demand, AI Monetization Efforts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Federal Reserve

Tech

ETFs

$BTC

AAPL

AMGN

AMZN

BKNG

CMCSA

COIN

CTRA

CVNA

SPDR Dow Jones Industrial Average ETF Trust

EBAY

INTC

MSFT

MSTR

NCLH

REGN

SBUX

TEAM

UBER

Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?

On Thursday,&nbsp;Cigna Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)&nbsp;reported third-quarter sales of $63.7 billion, up 30% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $59.35 billion</a>.
The increase was primarily driven by significant growth in Evernorth Health Services, reflecting large client wins and strong <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41647217/the-cigna-group-reports-strong-third-quarter-2024-results-reaffirms-2024-adjusted-eps-outlook" rel="noreferrer noopener">specialty volume growth</a>.
Adjusted income from operations&nbsp;for the third quarter of 2024 increased by 5%, reflecting strong contributions from Evernorth Health Services, particularly within Specialty and Care Services, partially offset by lower net investment income.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41399396/pharmacy-retailer-cvs-health-backs-away-from-annual-forecast-names-new-ceo" rel="noreferrer noopener">Pharmacy Retailer CVS Health Backs Away From Annual Forecast, Names New CEO</a>
Cigna Healthcare sales increased 3% to&nbsp;$13.16 billion, reflecting premium rate increases to cover expected increases in underlying medical costs, partially offset by a decrease in Individual and Family Plans customers.
Cigna's medical cost ratio – or spending on claims as a percentage of premiums – was 82.8% compared to 80.5% a year ago, reflecting the business mix and one extra business day in the third quarter of 2024.
Total premiums during the quarter rose 4.0% to $11.44 billion.&nbsp;
Evernorth Health Services sales increased 36%&nbsp;to&nbsp;$52.64 billion. Pharmacy Benefit Services sales increased 50% to $28.79 billion.
The total number of medical customers fell 2.9% to 19.05 million. Total customer relationships increased 12% to 183.51 million.
Total pharmacy customers increased 22% to 120 million. The adjusted EPS of $7.51, increased from $6.77 a year ago, beat the Wall Street estimate of $7.20.
Guidance:&nbsp;Cigna reaffirms 2024 adjusted EPS&nbsp;guidance&nbsp;of at least&nbsp;$28.40&nbsp;versus <a target="_blank" href="https://www.benzinga.com/news/earnings/24/08/40107403/cignas-q2-profit-beats-analyst-estimates-as-evernorth-health-services-growth-builds-momentum-reiter" rel="noreferrer noopener">consensus of&nbsp;$28.50</a>. The company expects a fiscal year 2024 medical cost ratio of 81.7%-82.5%.
Price Action: CI stock is up 3.93% at $325.18 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41655052/bristol-myers-squibb-boosts-2024-outlook-on-strong-demand-for-blood-thinner-med-new-drugs-drive-q" target="_blank" rel="noreferrer noopener">Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit</a></li>
</ul>
Photo via Shutterstock

Earnings

Guidance

Movers

Trading Ideas

Cigna's Q3 Profit Beats Street On Strong Demand For Pharmacy Benefit Management's Specialty Drugs, New Clients

WIIM

Cigna shares are trading higher following better-than-expected Q3 financial results.

Cigna Expects Full Year 2024 Medical Care Ratio Of 81.7%-82.5%

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">2024 Outlook</td>
<td colspan="1" rowspan="1">
Projection for Full Year Ending
December 31, 2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Income from Operations, per share</td>
<td colspan="1" rowspan="1">at least $28.40</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Evernorth Adjusted Income from Operations, Pre-Tax</td>
<td colspan="1" rowspan="1">at least $7,000</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Adjusted Income from Operations, Pre-Tax</td>
<td colspan="1" rowspan="1">at least $4,775</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Cigna Healthcare Medical Care Ratio</td>
<td colspan="1" rowspan="1">81.7% to 82.5%</td>
</tr>
</tbody>
</table>
</figure>

Cigna Reaffirms Full Year 2024 Consolidated Adjusted EPS From Operations Of At Least $28.40 Versus Consensus Of $28.5

Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) reported quarterly earnings of $7.51 per share which beat the analyst consensus estimate of $7.20 by 4.31 percent. The company reported quarterly sales of $63.70 billion which beat the analyst consensus estimate of $59.35 billion by 7.33 percent. This is a 29.79 percent increase over sales of $49.08 billion the same period last year.

Cigna Group Q3 2024 Adj EPS $7.51 Beats $7.20 Estimate, Sales $63.70B Beat $59.35B Estimate

KindlyMD now provides more than 90% statewide comprehensive insurance coverage
SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / KindlyMD, Inc. ("KindlyMD" or the "Company") (NASDAQ:<a href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>), a patient-first healthcare and healthcare data company uniquely integrating traditional primary care and pain management strategies with integrated behavioral and alternative therapies, today announced it is now contracted with Cigna Healthcare, after receiving additional credentialing.
Cigna's innovative approach to behavioral health focuses on integrating mental health services with primary care and ensuring that individuals receive comprehensive support tailored to their unique needs. The inclusion of Cigna Healthcare marks another significant milestone for the Company, which has recently emerged as one of the first alternative medical treatment providers in the state to achieve this prestigious status, alongside contracts with Select Health, Medicare, and Medicaid. Following this achievement, KindlyMD also announced its contract with Blue Cross Blue Shield and United Healthcare, further solidifying its position in the healthcare landscape.

KDLY

KindlyMD Announces New Partnership With Cigna Healthcare To Further Expand Patient Care Accessibility; KindlyMD Now Provides More Than 90% Statewide Comprehensive Insurance Coverage

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Broadcom Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41401505/broadcom-marvell-set-to-lead-in-2025-as-semiconductor-sector-is-at-the-cusp-of-a-se">is a buy</a>.
On Oct. 14, Mizuho analyst Vijay Rakesh maintained Broadcom with an Outperform and raised the price target from $190 to $220.
The &#8220;Mad Money&#8221; host recommended staying away from Blue Bird Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>). &#8220;I just don't see the growth,&#8221; he noted.
On Oct. 9, BTIG analyst Gregory Lewis initiated coverage on Blue Bird with a Buy rating and announced a price target of $55.
Cramer likes The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>). &#8220;It's two <a href="https://www.benzinga.com/quote/CI">thumb up,&#8221; he added.</a>
On Wednesday, Cigna's board declared a cash dividend of $1.40 per share of its common stock, payable on Dec. 19, to shareholders of record as of the close of business on Dec. 4.
Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) has &#8220;just been clobbered already,&#8221; Cramer said. &#8220;I don't want you to sell it all the way down here.&#8221;
On Oct. 22, Enphase Energy reported third-quarter revenue of $380.9 million, missing the consensus estimate of $391.979 million. The solar company reported adjusted earnings of 65 cents per share, missing analyst estimates of 77 cents per share, according to Benzinga Pro.
Cramer recommended staying away from ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>).
On Wednesday, Barclays analyst Alexia Dogani maintained ZIM Integrated Shipping with an Underweight and raised the price target from $12.30 to $13.90.
Price Action:
<ul>
<li>Enphase Energy shares gained 3.4% to settle at $81.10 on Thursday.</li>
<li>Cigna shares gained 0.2% to close at $318.24.</li>
<li>Zim Integrated Shipping shares rose 0.9% to settle at $22.66 during the session.</li>
<li>Broadcom shares fell 1.2% to settle at $171.35 on Thursday.</li>
<li>Blue Bird shares fell 1.7% to close at $41.16 during the session.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/10/41528323/jim-cramer-says-hold-on-to-palantir-let-them-walk-it-up-warns-that-travere-therapeutics-is-losing-a">Jim Cramer Says &#8216;Hold On&#8217; To Palantir, &#8216;Let Them Walk It Up&#8217;; Warns That Travere Therapeutics Is Losing A &#8216;Ton Of Money&#8217;</a></li>
</ul>
Image: Shutterstock

Long Ideas

Media

AVGO

BLBD

ENPH

Jim Cramer: Buy Broadcom, But Stay Away From These Stocks

11 analysts have shared their evaluations of Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Cigna, revealing an average target of $405.36, a high estimate of $438.00, and a low estimate of $384.00. Marking an increase of 0.79%, the current average surpasses the previous average price target of $402.18. 
<img src="https://www.benzinga.com/files/images/story/2024/1729702811_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Cigna among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$422.00</td>
<td>$402.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$384.00</td>
<td>$384.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$438.00</td>
<td>$435.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$410.00</td>
<td>$410.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$405.00</td>
<td>$393.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cigna. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cigna compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Cigna's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Cigna's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cigna analyst ratings.</a>
<h2>Discovering Cigna: A Closer Look</h2>
Cigna primarily provides pharmacy benefit management and health insurance services. Its PBM and specialty pharmacy services, which were greatly expanded by its 2018 merger with Express Scripts, are mostly sold to health insurance plans and employers. Its largest PBM contract is the Department of Defense, and it recently won a deal with top-tier insurer Centene. In health insurance and other benefits, Cigna mostly serves employers through self-funding arrangements, and the company operates mostly in the US with 18 million US medical members covered as of December 2023.
<h3>Key Indicators: Cigna's Financial Health</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Cigna's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 24.4%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Cigna's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 2.56%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Cigna's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.75% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Cigna's ROA stands out, surpassing industry averages. With an impressive ROA of 1.0%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Cigna's debt-to-equity ratio is below the industry average. With a ratio of 0.77, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

11 Analysts Assess Cigna: What You Need To Know

Cantor Fitzgerald analyst Sarah James reiterates Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and maintains $400 price target.

Cantor Fitzgerald Reiterates Overweight on Cigna, Maintains $400 Price Target

Cigna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has outperformed the market over the past 15 years by 5.39% on an annualized basis producing an average annual return of 17.33%. Currently, Cigna has a market capitalization of $88.27 billion. 
Buying $1000 In CI: If an investor had bought $1000 of CI stock 15 years ago, it would be worth $11,461.52 today based on a price of $315.76 for CI at the time of writing.
<h3>Cigna's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729697415_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Cigna Stock In The Last 15 Years

U.S. major indices fell on Monday as rising Treasury yields and a strengthening dollar dampened risk sentiment. Investors are reassessing the economic outlook and weighing potential risks tied to the Federal Reserve&#8217;s <a href="https://www.benzinga.com/topic/interest-rates">next interest rate moves.</a>
Yields on the 10-year Treasury note surged 9 basis points to 4.18%, reaching their highest level since late July. Meanwhile, 30-year Treasury bond yields climbed to 4.5%. The spike in yields pushed the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) down by 1.4%, reflecting renewed pressure on long-duration bonds.
A gauge of the greenback, as tracked by Invesco DB USD Index Bullish Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rose 0.5%. 
On Monday, Dallas Fed President Lorie Logan hinted that gradual rate cuts are on the cards if the economy meets forecasts. Market-implied expectations for a 25-basis-point rate cut in November dipped slightly from 90% to 85%, according to CME FedWatch.
The CBOE Volatility Index (VIX), commonly known as Wall Street's "fear gauge," jumped 5% on Monday, marking its largest surge in two weeks.
The S&amp;P 500 traded 0.5% lower at midday trading in New York, with all its 11 sectors in the red. The Dow Jones Industrial Average shed 0.9%, while the Russell 2000, which tracks small-cap stocks, tumbled 1.7%. Technology stocks experienced minor losses. 
Despite the negative session, NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained over 2%, hitting $141.80 per share and notching fresh all-time highs.
In commodities, gold took a breather after four consecutive sessions of gains, while oil prices rebounded 1.6%, driven by renewed supply concerns. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell sharply, losing 2.8%. 
<h1 class="wp-block-heading">Monday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,290.48</td>
<td>-0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,840.64</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,904.60</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,237.90</td>
<td>-1.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:55 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent101824&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.3% to $582.24.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.7% to $429.46.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) eased 0.2% to $493.66.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) dipped to $222.12.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 0.9%. The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.6%.</li>
</ul>
<h1 class="wp-block-heading">Monday&#8217;s Stock Movers</h1>
<ul>
<li>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) surged over 3% after the company reached a preliminary agreement with its employees to end a five-week strike. Adding to the momentum, Emirates SkyCargo placed an order for five additional Boeing 777 freighters. </li>
<li>Kenvue Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>) shares jumped 6.5% following reports that activist investor Starboard Value has acquired a substantial stake in the company.</li>
<li>Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) extended its losses on Monday, falling nearly 5% after a 5% decline on Friday, as investors continued to react negatively to reports of a potential merger with Humana Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>). Oppenheimer analysts weighed in on the situation, recommending that Cigna remain independent amid skepticism about the merger's strategic value and regulatory feasibility.</li>
</ul>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41431485/goldman-sachs-predicts-bleak-long-term-s-p-500-returns-as-market-concentration-hits">Goldman Sachs Predicts Bleak Long-Term S&amp;P 500 Returns As Market Concentration Hits &#8216;Highest Level In 100 Years&#8217;</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Bonds

Currency ETFs

Forex

Treasuries

KVUE

NVDA

iShares Trust Barclays 20+ Year Treasury Bond Fund

PowerShares DB US Dollar Index Bullish Fund

Stocks Fall As Treasury Yields, Dollar Rise; Nvidia Hits Record Highs: What's Driving Markets Monday?

In a significant development in the health insurance industry, Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) has reinitiated discussions to merge with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), potentially creating a giant in the sector.
Talks, previously stalled over pricing disagreements, have resumed with a focus on a transformative consolidation that could reshape market dynamics.
According to a <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-10-18/cigna-resumes-merger-discussions-with-humana-after-talks-ended-last-year?sref=TBDibEcD" rel="noreferrer noopener">Bloomberg</a> report on Friday, the early talks about the merger would significantly expand Cigna&#8217;s footprint in Medicare Advantage alongside its commercial insurance prowess while leveraging Humana&#8217;s strong Medicare segment.
Also: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/09/40964870/us-federal-trade-commission-sues-cvs-health-cigna-unitedhealths-pharmacy-benefit-managers-for-infl" rel="noreferrer noopener">US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth&#8217;s Pharmacy Benefit Managers For Inflating Insulin Prices</a>
Last year, both <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/36007194/whats-going-on-with-healthcare-insurance-giant-cigna-stock-today" rel="noreferrer noopener">companies faced challenges</a> as they navigated federal pressures to reduce Medicare costs, severely impacting Humana&#8217;s market performance and valuation.
These resumed talks hint at a possible major realignment aiming to fortify their positions against competitors like UnitedHealth Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) and&nbsp;CVS Health Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>).
The merger discussions are still in the nascent stages, with no decisions made. Both companies declined to comment on the ongoing negotiations.
A potential deal, estimated to be among the top five health insurance mergers, reflects a strategic shift in the industry focused on consolidation amid rising healthcare costs and stringent regulatory environments.
This deal could not only stabilize Humana&#8217;s declining Medicare enrollments but also enhance Cigna&#8217;s capabilities in managing more comprehensive healthcare plans.
Furthermore, a merger could ease the competitive pressure from the rapidly growing sectors of the industry, providing a robust challenge to established giants.
Humana&#8217;s stock value sharply declined due to lower-than-expected government reimbursements and increased demand for medical services. The merger is, therefore, potentially crucial for recovery and growth.
Price Action: CI stock is down 4.18% at $321.94, and HUM stock is up 0.88% at $269.50 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41409405/after-failed-confirmatory-trial-gilead-withdraws-us-accelerated-approval-of-trodelvy-as-bladder-c" target="_blank" rel="noreferrer noopener">After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer Treatment</a>.</li>
</ul>
Photo via Shutterstock

Rumors

Cigna And Humana Revive Early Merger Talks After Year-Long Pause As Medicare Cost Pressure Looms

The Cigna Group shares are trading lower after a report suggesting the company has resumed merger discussions with Humana.

With U.S. stock futures trading mixed this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) to report quarterly earnings at $1.33 per share on revenue of $9.29 billion after the closing bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. SAP shares gained 0.2% to $230.87 in after-hours trading.</li>
<li>Public Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSA#NYSE">PSA</a>) named Chris Sambar as COO. Public Storage shares gained 0.1% to close at $345.62 on Friday.</li>
<li>Analysts are expecting Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) to post quarterly earnings at $1.47 per share on revenue of $7.28 billion. The company will release earnings after the markets close. Nucor shares gained 0.1% to close at $158.24 on Friday.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) shares fell in after-hours trading after a report suggesting the company has resumed merger discussions with Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) after the conversation ended last year. Cigna shares fell 4.7% to $320.26 in the after-hours trading session.</li>
<li>Analysts expect Logitech International S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOGI#NASDAQ">LOGI</a>) to report quarterly earnings at 99 cents per share on revenue of $1.11 billion after the closing bell. Logitech shares rose 1.2% to close at $88.63 on Friday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41402086/wall-streets-most-accurate-analysts-give-their-take-on-3-financials-stocks-delivering-hi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financials Stocks Delivering High-Dividend Yields</a></li>
</ul>
Photo courtesy: SAP

Pre-Market Outlook

LOGI

SAP, Nucor And 3 Stocks To Watch Heading Into Monday

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alphatec Holdings (ATEC – Research Report), Cigna ...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Alphatec Holdings (ATEC), Cigna (CI) and Intuitive Surgical (ISRG)

Cigna (CI) Healthcare and Mobile-based Infirmary Health have reached an agreement that allows Cigna Healthcare's Medicare Advantage customers to ha...

Comments

Cigna

Notizie

Ultime notizie per Cigna (NYSE:CI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO